Credit Suisse’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Credit Suisse’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,704	Closed	-$1.04M	–	4636
2021 Q1	$1.04M	Sell	20,704 -14,629	-41%	-$780K	﹤0.01%	3293
2020 Q4	$1.84M	Buy	35,333 +10,730	+44%	+$513K	﹤0.01%	2888
2020 Q3	$1.07M	Sell	24,603 -3,104	-11%	-$136K	﹤0.01%	2874
2020 Q2	$1.19M	Buy	+27,707	New	+$1.15M	﹤0.01%	2777
2020 Q1	–	Sell	-1,236,914	Closed	-$56.5M	–	4284
2019 Q4	$56.5M	Sell	1,236,914 -378,791	-23%	-$15M	0.04%	481
2019 Q3	$57.5M	Buy	1,615,705 +442,105	+38%	+$16.4M	0.05%	411
2019 Q2	$46.7M	Sell	1,173,600 -118,172	-9%	-$4.65M	0.04%	472
2019 Q1	$53.7M	Buy	+1,291,772	New	+$52.5M	0.05%	398
2018 Q4	–	Sell	-4,598	Closed	-$223K	–	4033
2018 Q3	$223K	Buy	+4,598	New	+$218K	﹤0.01%	3624
2017 Q4	–	Sell	-35,520	Closed	-$1.51M	–	4232
2017 Q3	$1.51M	Hold	35,520	–	–	﹤0.01%	2788
2017 Q2	$1.53M	Sell	35,520 -736	-2%	-$31K	﹤0.01%	2406
2017 Q1	$1.52M	Buy	36,256 +15,891	+78%	+$648K	﹤0.01%	2558
2016 Q4	$796K	Sell	20,365 -15,394	-43%	-$626K	﹤0.01%	3180
2016 Q3	$1.58M	Buy	+35,759	New	+$1.62M	﹤0.01%	2559
2016 Q2	–	Sell	-10,904	Closed	-$439K	–	4369
2016 Q1	$439K	Sell	10,904 -77,271	-88%	-$3.27M	﹤0.01%	3322
2015 Q4	$4.51M	Sell	88,175 -33,391	-27%	-$1.7M	0.01%	1665
2015 Q3	$5.7M	Buy	121,566 +10,384	+9%	+$626K	0.01%	1470
2015 Q2	$6.93M	Sell	111,182 -48,856	-31%	-$3.04M	0.01%	1480
2015 Q1	$9.88M	Buy	160,038 +69,026	+76%	+$4.09M	0.01%	1202
2014 Q4	$4.91M	Buy	91,012 +44,488	+96%	+$2.43M	﹤0.01%	1772
2014 Q3	$2.47M	Buy	+46,524	New	+$2.37M	﹤0.01%	2325
2014 Q2	–	Sell	-58,642	Closed	-$2.75M	–	4824
2014 Q1	$2.75M	Buy	58,642 +1,580	+3%	+$74.6K	﹤0.01%	2268
2013 Q4	$2.51M	Buy	57,062 +44,142	+342%	+$1.84M	﹤0.01%	2460
2013 Q3	$497K	Sell	12,920 -524,852	-98%	-$19.8M	﹤0.01%	3498
2013 Q2	$19M	Buy	+537,772	New	+$18.2M	0.02%	778

Other funds holding XPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return

Credit Suisse's XPH Position: Q2 2021 in Review

Credit Suisse sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2021, closing a stake of 20,704 shares — an estimated $1.04M sold.

Credit Suisse first reported a position in XPH in Q2 2013 and held it in 25 quarters. The position peaked at $57.5M in Q3 2019. 79 funds tracked by Wall St. Rank hold XPH as of Q2 2021.

Credit Suisse reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2021 after selling out during the quarter.
Credit Suisse sold 20,704 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2021, an estimated $1.04M.
Credit Suisse first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 25 quarters.
Credit Suisse's State Street SPDR S&P Pharmaceuticals ETF position peaked at $57.5M in Q3 2019.
79 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.